A Phase Ib, Double-Masked, Multiple-Ascending Dose Trial to Evaluate an Eye Drop Formulation of AKB-9778 for Treatment of Primary Open Angle Glaucoma (POAG)
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Razuprotafib (Primary)
- Indications Open-angle glaucoma
- Focus Adverse reactions
- Sponsors Aerpio Pharmaceuticals
- 07 Nov 2019 According to an Aerpio Pharmaceuticals media release, dosing of the first three cohorts of healthy subjects is completed.
- 10 Oct 2019 According to an Aerpio Pharmaceuticals media release, full results from the trial are expected in the first quarter of 2020.
- 10 Oct 2019 Interim results published in the Aerpio Pharmaceuticals media release.